These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37978951)

  • 1. Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial.
    Haas-Kogan DA; Aboian MS; Minturn JE; Leary SES; Abdelbaki MS; Goldman S; Elster JD; Kraya A; Lueder MR; Ramakrishnan D; von Reppert M; Liu KX; Rokita JL; Resnick AC; Solomon DA; Phillips JJ; Prados M; Molinaro AM; Waszak SM; Mueller S
    J Clin Oncol; 2024 Feb; 42(4):441-451. PubMed ID: 37978951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas.
    Wahl M; Chang SM; Phillips JJ; Molinaro AM; Costello JF; Mazor T; Alexandrescu S; Lupo JM; Nelson SJ; Berger M; Prados M; Taylor JW; Butowski N; Clarke JL; Haas-Kogan D
    Cancer; 2017 Dec; 123(23):4631-4639. PubMed ID: 28759109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
    Fangusaro J; Onar-Thomas A; Young Poussaint T; Wu S; Ligon AH; Lindeman N; Banerjee A; Packer RJ; Kilburn LB; Goldman S; Pollack IF; Qaddoumi I; Jakacki RI; Fisher PG; Dhall G; Baxter P; Kreissman SG; Stewart CF; Jones DTW; Pfister SM; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Fisher MJ; Doyle LA; Smith M; Dunkel IJ; Fouladi M
    Lancet Oncol; 2019 Jul; 20(7):1011-1022. PubMed ID: 31151904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
    van Tilburg CM; Kilburn LB; Perreault S; Schmidt R; Azizi AA; Cruz-Martínez O; Zápotocký M; Scheinemann K; Meeteren AYNS; Sehested A; Opocher E; Driever PH; Avula S; Ziegler DS; Capper D; Koch A; Sahm F; Qiu J; Tsao LP; Blackman SC; Manley P; Milde T; Witt R; Jones DTW; Hargrave D; Witt O
    BMC Cancer; 2024 Jan; 24(1):147. PubMed ID: 38291372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
    Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
    J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.
    Olow A; Mueller S; Yang X; Hashizume R; Meyerowitz J; Weiss W; Resnick AC; Waanders AJ; Stalpers LJ; Berger MS; Gupta N; James CD; Petritsch CK; Haas-Kogan DA
    Clin Cancer Res; 2016 Nov; 22(21):5312-5321. PubMed ID: 27217440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma.
    Wright KD; Yao X; London WB; Kao PC; Gore L; Hunger S; Geyer R; Cohen KJ; Allen JC; Katzenstein HM; Smith A; Boklan J; Nazemi K; Trippett T; Karajannis M; Herzog C; Destefano J; Direnzo J; Pietrantonio J; Greenspan L; Cassidy D; Schissel D; Perentesis J; Basu M; Mizuno T; Vinks AA; Prabhu SP; Chi SN; Kieran MW
    Pediatr Blood Cancer; 2021 Feb; 68(2):e28787. PubMed ID: 33140540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants.
    Lin A; Rodriguez FJ; Karajannis MA; Williams SC; Legault G; Zagzag D; Burger PC; Allen JC; Eberhart CG; Bar EE
    J Neuropathol Exp Neurol; 2012 Jan; 71(1):66-72. PubMed ID: 22157620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
    Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
    BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study.
    Ullrich NJ; Prabhu SP; Reddy AT; Fisher MJ; Packer R; Goldman S; Robison NJ; Gutmann DH; Viskochil DH; Allen JC; Korf B; Cantor A; Cutter G; Thomas C; Perentesis JP; Mizuno T; Vinks AA; Manley PE; Chi SN; Kieran MW
    Neuro Oncol; 2020 Oct; 22(10):1527-1535. PubMed ID: 32236425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study.
    Lassaletta A; Scheinemann K; Zelcer SM; Hukin J; Wilson BA; Jabado N; Carret AS; Lafay-Cousin L; Larouche V; Hawkins CE; Pond GR; Poskitt K; Keene D; Johnston DL; Eisenstat DD; Krishnatry R; Mistry M; Arnoldo A; Ramaswamy V; Huang A; Bartels U; Tabori U; Bouffet E
    J Clin Oncol; 2016 Oct; 34(29):3537-3543. PubMed ID: 27573663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in
    Usta D; Sigaud R; Buhl JL; Selt F; Marquardt V; Pauck D; Jansen J; Pusch S; Ecker J; Hielscher T; Vollmer J; Sommerkamp AC; Rubner T; Hargrave D; van Tilburg CM; Pfister SM; Jones DTW; Remke M; Brummer T; Witt O; Milde T
    Mol Cancer Ther; 2020 Aug; 19(8):1736-1750. PubMed ID: 32451331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiplex Detection of Pediatric Low-Grade Glioma Signature Fusion Transcripts and Duplications Using the NanoString nCounter System.
    Ryall S; Arnoldo A; Krishnatry R; Mistry M; Khor K; Sheth J; Ling C; Leung S; Zapotocky M; Guerreiro Stucklin A; Lassaletta A; Shago M; Tabori U; Hawkins CE
    J Neuropathol Exp Neurol; 2017 Jul; 76(7):562-570. PubMed ID: 28863456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.
    Ho CY; Mobley BC; Gordish-Dressman H; VandenBussche CJ; Mason GE; Bornhorst M; Esbenshade AJ; Tehrani M; Orr BA; LaFrance DR; Devaney JM; Meltzer BW; Hofherr SE; Burger PC; Packer RJ; Rodriguez FJ
    Acta Neuropathol; 2015 Oct; 130(4):575-85. PubMed ID: 26264609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic alterations related to BRAF-FGFR genes and dysregulated MAPK/ERK/mTOR signaling in adult pilocytic astrocytoma.
    Pathak P; Kumar A; Jha P; Purkait S; Faruq M; Suri A; Suri V; Sharma MC; Sarkar C
    Brain Pathol; 2017 Sep; 27(5):580-589. PubMed ID: 27608415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.
    Lassaletta A; Zapotocky M; Mistry M; Ramaswamy V; Honnorat M; Krishnatry R; Guerreiro Stucklin A; Zhukova N; Arnoldo A; Ryall S; Ling C; McKeown T; Loukides J; Cruz O; de Torres C; Ho CY; Packer RJ; Tatevossian R; Qaddoumi I; Harreld JH; Dalton JD; Mulcahy-Levy J; Foreman N; Karajannis MA; Wang S; Snuderl M; Nageswara Rao A; Giannini C; Kieran M; Ligon KL; Garre ML; Nozza P; Mascelli S; Raso A; Mueller S; Nicolaides T; Silva K; Perbet R; Vasiljevic A; Faure Conter C; Frappaz D; Leary S; Crane C; Chan A; Ng HK; Shi ZF; Mao Y; Finch E; Eisenstat D; Wilson B; Carret AS; Hauser P; Sumerauer D; Krskova L; Larouche V; Fleming A; Zelcer S; Jabado N; Rutka JT; Dirks P; Taylor MD; Chen S; Bartels U; Huang A; Ellison DW; Bouffet E; Hawkins C; Tabori U
    J Clin Oncol; 2017 Sep; 35(25):2934-2941. PubMed ID: 28727518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabrafenib plus trametinib in patients with BRAF
    Wen PY; Stein A; van den Bent M; De Greve J; Wick A; de Vos FYFL; von Bubnoff N; van Linde ME; Lai A; Prager GW; Campone M; Fasolo A; Lopez-Martin JA; Kim TM; Mason WP; Hofheinz RD; Blay JY; Cho DC; Gazzah A; Pouessel D; Yachnin J; Boran A; Burgess P; Ilankumaran P; Gasal E; Subbiah V
    Lancet Oncol; 2022 Jan; 23(1):53-64. PubMed ID: 34838156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.
    Treilleux I; Arnedos M; Cropet C; Wang Q; Ferrero JM; Abadie-Lacourtoisie S; Levy C; Legouffe E; Lortholary A; Pujade-Lauraine E; Bourcier AV; Eymard JC; Spaeth D; Bachelot T
    Ann Oncol; 2015 Jan; 26(1):120-125. PubMed ID: 25361980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin.
    Poore B; Yuan M; Arnold A; Price A; Alt J; Rubens JA; Slusher BS; Eberhart CG; Raabe EH
    Neuro Oncol; 2019 Feb; 21(2):252-263. PubMed ID: 30239952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Dabrafenib in Pediatric Patients with
    Hargrave DR; Bouffet E; Tabori U; Broniscer A; Cohen KJ; Hansford JR; Geoerger B; Hingorani P; Dunkel IJ; Russo MW; Tseng L; Dasgupta K; Gasal E; Whitlock JA; Kieran MW
    Clin Cancer Res; 2019 Dec; 25(24):7303-7311. PubMed ID: 31811016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.